| Author | Johnson, Margaret | |
| Author | Grinsztejn, Beatriz | |
| Author | Rodriguez, Claudia | |
| Author | Coco, Jeffrey | |
| Author | DeJesus, Edwin | |
| Author | Lazzarin, Adriano | |
| Author | Lichtenstein, Kenneth | |
| Author | Rightmire, Anna | |
| Author | Sankoh, Serap | |
| Author | Wilber, Richard | |
| Access date | 2019-01-28T15:29:02Z | |
| Available date | 2019-01-28T15:29:02Z | |
| Document date | 2005 | |
| Citation | JOHNSON, Margaret et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS, v. 19, n. 7, p. 685-694, 2005. | pt_BR |
| ISSN | 0269-9370 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/31329 | |
| Description | Comment in: Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles? [AIDS. 2005]. | en_US |
| Description | Corrected and republished from: Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. [AIDS. 2005] | en_US |
| Language | eng | pt_BR |
| Publisher | Lippincott, Williams & Wilkins | pt_BR |
| Rights | restricted access | pt_BR |
| Title | Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures | pt_BR |
| Type | Article | |
| DOI | 10.1097/01.aids.0000166091.39317.99 | |
| Abstract | OBJECTIVE: To evaluate atazanavir/ritonavir (ATV/RTV) (300/100 mg) once daily, atazanavir/saquinavir (ATV/SQV) (400/1200 mg) once daily, and lopinavir/ritonavir (LPV/RTV) (400/100 mg) twice daily, each with tenofovir (300 mg) once daily and a nucleoside reverse transcriptase inhibitor in treatment-experienced HIV-infected patients. METHODS: Randomized, open-label, 48-week multicenter trial of 358 randomized adult patients who had failed two or more prior HAART regimens with baseline HIV RNA > or = 1000 copies/ml and CD4 cell count > or = 50 x 10(6) cells/l. RESULTS: The primary efficacy endpoint [plasma HIV RNA reduction assessed by time-averaged difference (TAD)] was similar for ATV/RTV and LPV/RTV [TAD 0.13; 97.5% confidence interval, -0.12 to 0.39] at 48 weeks. Mean reductions from baseline for ATV/RTV and LPV/RTV were comparable at 1.93 and 1.87 log10 copies/ml, respectively. Mean CD4 cell count increases were 110 and 121 x 10(6) cells/l for ATV/RTV, and LPV/RTV, respectively. The efficacy of ATV/SQV was lower than LPV/RTV by both these parameters. Declines in total cholesterol and fasting triglycerides were greater with ATV/RTV and ATV/SQV than with LPV/RTV (P < or = 0.005). Lipids in the LPV/RTV arm at week 48 generally increased from baseline. Lipid-lowering agents were used more frequently in the LPV/RTV arm than in the ATV arms (P < 0.05 versus ATV/RTV), as were antidiarrheal agents (P < or = 0.04 versus both ATV treatments). No new or unique safety findings emerged. CONCLUSIONS: ATV boosted with RTV is as effective and well tolerated as LPV/RTV in treatment-experienced patients, with a more favorable impact on serum lipids. Pharmacokinetically enhanced ATV provides a suitable choice for therapy of treatment-experienced HIV-infected patients. | en_US |
| Affilliation | Royal Free Hospital. London, UK. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Hospital Argerich. Buenos Aires, Argentina. | pt_BR |
| Affilliation | Pendleton Memorial Methodist Hospital. New Orleans, Louisiana, USA. | pt_BR |
| Affilliation | IDC Research Initiative. Altamonte Springs, Florida, USA. | pt_BR |
| Affilliation | S. Raffaele Hospital. Milan, Italy. | pt_BR |
| Affilliation | University of Colorado Health Sciences. Denver, Colorado, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb Pharmaceutical Research Institute. Wallingford, Connecticut, USA. | pt_BR |
| Affilliation | Bristol- Myers Squibb Pharmaceutical Research Institute. Hopewell, New Jersey, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb Pharmaceutical Research Institute. Wallingford, Connecticut, USA. | pt_BR |
| Subject | Antiretroviral therapy | pt_BR |
| Subject | Atazanavir | pt_BR |
| Subject | Lipids | pt_BR |
| Subject | Lopinavir | pt_BR |
| Subject | Protease Inhibitors | pt_BR |
| Subject | Ritonavir | pt_BR |
| Subject | Saquinavir | pt_BR |
| e-ISSN | 1473-5571 | |
| Embargo date | 2028-01-01 | |
